Cirrhosis

Cirrhosis is a condition in which the liver slowly deteriorates and malfunctions due to chronic injury. Scar tissue replaces healthy liver tissue, partially blocking the flow of blood through the liver.

What is Cirrhosis?

Cirrhosis is a severe form of liver disease wherein normal liver tissue is replaced by scar tissue (fibrous tissue).

What Causes Cirrhosis?

Managing and Treating Cirrhosis

Liver Disease Symptoms

Improving fatty liver diagnosis through AI analysis of standard chest radiographs

Fatty liver disease, caused by the accumulation of fat in the liver, is estimated to affect one in four people worldwide. If left untreated, it can lead to serious complications, such as cirrhosis and liver cancer, making it crucial to detect early and initiate treatment.

27 Jun 2025

Ribosome biogenesis plays critical role in liver health and disease progression

This new review article highlights the critical role of ribosome biogenesis in liver health and disease progression.

25 Jun 2025

New molecular imaging agent shows high accuracy in detecting liver cancer

A novel molecular imaging agent targeting glypican-3 (GPC3) has demonstrated high sensitivity and specificity in detecting hepatocellular carcinoma (HCC), including tumors smaller than one centimeter, according to results from a pilot clinical study.

23 Jun 2025

New intercellular network found to drive liver fibrosis progression

Liver fibrosis, a pathological condition in which the liver becomes stiff and scarred, commonly develops in the progression of chronic liver diseases such as chronic hepatitis and metabolic dysfunction-associated steatohepatitis (MASH).

21 Jun 2025

Circular RNAs emerge as key players in hepatitis B-related liver cancer

Hepatitis B virus-induced hepatocellular carcinoma (HCC) remains a major global health burden, and new therapeutic and diagnostic approaches are urgently needed.

20 Jun 2025

Fatty liver found in majority of type 2 diabetes patients

Six out of ten people with type 2 diabetes had fatty liver in a new study from Linköping University. Of these, only a small percentage had developed more severe liver disease.

17 Jun 2025

Chronic hyponatremia causes anxiety-like behaviors by disrupting brain chemistry

Hyponatremia, or low blood sodium concentration, is typically viewed as a symptomless condition-until recently.

12 Jun 2025

Waist-to-height ratio found to predict liver damage better than BMI

Excess fat mass estimated by waist circumference-to-height ratio predicts the risk of liver damage better than body mass index (BMI) estimated obesity, a new study shows.

11 Jun 2025

Rising liver disease cases demand immediate attention

During the first meeting of the Global Think-tank on Steatotic Liver Disease, supported by the Barcelona Institute for Global Health (ISGlobal) and held in the Palau Macaya of Barcelona on 5–6 June, more than 100 international experts issued a stark warning: millions of people will continue to go unseen by healthcare systems unless early detection and person-centred care for liver disease are prioritized without delay.

6 Jun 2025

Type 2 diabetes drug shows improvements for patients with progressive liver disease

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows improvements for patients with progressive liver disease, finds a clinical trial from China published by The BMJ today.

5 Jun 2025

Hormone FGF21 reverses fatty liver disease by signaling the brain

A pioneering research study published today in Cell Metabolism details how the hormone FGF21 (fibroblast growth factor 21) can reverse the effects of fatty liver disease in mice. The hormone works primarily by signaling the brain to improve liver function.

13 May 2025

Low income linked to higher risk of dying from liver cancer

The risk of dying from the most common form of primary liver cancer is about 30 percent higher for patients with low household income compared to those with middle or high household income, according to a study at the University of Gothenburg.

5 May 2025

Semaglutide clears liver inflammation and cuts fibrosis in MASH patients, trial shows

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic dysfunction-associated steatohepatitis (MASH). The interim results also reveal meaningful weight loss and improved cardiometabolic markers, with a favorable safety profile.

4 May 2025

Semaglutide shows promise in treating severe liver disease

Semaglutide effectively treats liver disease in two thirds of patients, new research has found.

30 Apr 2025

MASLD in children linked to increased mortality and chronic complications

Researchers from University of California San Diego have found that children diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD) are at significantly increased risk of premature death and serious long-term health complications.

28 Apr 2025